Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Dec:21:431-9.

Megestrol acetate

No authors listed
  • PMID: 296136

Megestrol acetate

No authors listed. IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec.

Abstract

PIP: This monograph on megestrol acetate (MA) includes its chemical and physical data (synonyms and trade names), its structural and molecular formulae and molecular weight, chemical and physical properties (melting point, optical rotation, solubility, etc.), and its production, use, occurrence, and analysis. MA, which is not known to occur naturally, is produced by dehydrogenation of medroxyprogesterone acetate with chloranil. Its use in human medicine is for treatment of endometrial and breast carcinomas, as well as for treatment of acne, hirsutism, and sexual infantilism in females. Some countries, not including the U.S., use MA in combination oral contraceptive preparations. Typical analytical methods for determining the bulk chemical are presented tabularly. Biological data relevant to the evaluation of carcinogenic risk to humans are presented briefly. MA alone or with ethinyl estradiol has been tested in mice, rats, and dogs orally and in rats subcutaneously. Mammary tumors developed in dogs when treated with MA alone, and in mice when tested in combination with ethinyl estradiol. No case reports or human epidemiological studies of MA alone are available. It is concluded that there is limited evidence for the carcinogenicity of MA in dogs. In humans, oral contraceptives containing estrogens in combination with progestin have been related causally to an increased incidence of benign liver adenomas and a decreased incidence of benign breast disease.

PubMed Disclaimer

Similar articles

  • Chlormadinone acetate.
    [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:365-75. IARC Monogr Eval Carcinog Risk Chem Hum. 1979. PMID: 94586
  • Norethynodrel.
    [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:461-77. IARC Monogr Eval Carcinog Risk Chem Hum. 1979. PMID: 120839 Review.
  • Ethinyloestradiol.
    [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:233-55. IARC Monogr Eval Carcinog Risk Chem Hum. 1979. PMID: 120833 Review.
  • Norethisterone and norethisterone acetate.
    [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:441-60. IARC Monogr Eval Carcinog Risk Chem Hum. 1979. PMID: 120838 Review.
  • Medroxyprogesterone acetate.
    [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:417-29. IARC Monogr Eval Carcinog Risk Chem Hum. 1979. PMID: 120837
See all similar articles

LinkOut - more resources